ABSTRACT
Delavirdine mesylate, formerly known as U-90152, is a member of the bisheteroarylpiperazine (BHAP) class of nonnucleoside reverse transcriptase inhibitors discovered at UpJohn Laboratories in Kalamazoo, Michigan (Romero et al., 1991; Adams et al., 1998). Like other members of its class, it is an inhibitor of the HIV-1 reverse transcriptase but is inactive against HIV-2 or other retroviruses. Atevirdine (U-87201E) is a closely related compound of the same class (χ). Manufactured and previously marketed by Pfizer it is now marketed by ViiV Healthcare under the brand name Rescriptor.
